Journal article
Mineralocorticoid receptor antagonists in patients with chronic kidney disease
Abstract
Mineralocorticoid receptor antagonists (MRA) can reduce cardiovascular morbidity and mortality in patients with heart failure and ischemic heart disease. In addition, these agents have been used in patients with diabetic nephropathy to control proteinuria and slow down chronic kidney disease (CKD) progression. Current guidelines recommend against the use of MRAs in patients with advanced CKD. However, there is growing interest on their use in …
Authors
Cosimato C; Agoritsas T; Mavrakanas TA
Journal
Pharmacology & Therapeutics, Vol. 219, ,
Publisher
Elsevier
Publication Date
March 2021
DOI
10.1016/j.pharmthera.2020.107701
ISSN
0163-7258